Aptose Biosciences approved to escalate dose in Phase 1/2 AML trial
Aptose Biosciences (APTO) announced that the Cohort Safety Review Committee – CSRC – monitoring Aptose’s Phase 1/2 TUSCANY trial of tuspetinib ...